https://www.selleckchem.com/pr....oducts/ugt8-in-1.htm
In drug development, a crucial step is the transition of a company from preclinical stages to human trials the so-called 'Valley-of-Death' (VoD) that most efforts do not survive. Here, we analyzed how the valuations of biotech companies in the life science sector change as they cross this valley. Their average valuation increased significantly (87%) when crossing the VoD no later than their fourth funding round. However, companies that received more than four funding rounds saw significantly lower average valuations. Similarly, the vo
Like
Comment
Share
